Trials / Completed
CompletedNCT01104948
A Study to Characterize the Pharmacokinetics of DA-8031 in Healthy Male Subjects
A Dose Block-randomized, Double-blind, Placebo-controlled, Single/Multiple Dosing, Dose-escalation Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetic Characteristics of DA-8031 After Oral Administration in Healthy Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 106 (actual)
- Sponsor
- Dong-A Pharmaceutical Co., Ltd. · Industry
- Sex
- Male
- Age
- 20 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This is a dose block-randomized, double-blind, placebo-controlled, single/multiple dosing, dose-escalation study. The study is designed to describe the relationship between multiple doses and pharmacokinetic parameters of DA-8031 as well as safety profile.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DA-8031 | |
| DRUG | Placebo |
Timeline
- Start date
- 2010-05-01
- Primary completion
- 2011-10-01
- Completion
- 2011-10-01
- First posted
- 2010-04-16
- Last updated
- 2012-07-11
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01104948. Inclusion in this directory is not an endorsement.